An overview of amikacin

Area of Science:

• Pharmacology
• Infectious Diseases
• Microbiology

Background:

• Amikacin, a kanamycin analog, demonstrates broad-spectrum activity against Gram-negative bacteria.
• It is effective against strains resistant to gentamicin and tobramycin.
• Its resistance to inactivating enzymes makes it a key choice for serious Gram-negative infections.

Purpose of the Study:

• To evaluate the efficacy and suitability of amikacin as a preferred aminoglycoside antibiotic.
• To highlight its role in treating infections caused by resistant organisms.
• To discuss its use in immunocompromised patients and in combination therapies.

Main Methods:

• Review of existing clinical data and in vitro studies on amikacin.
• Analysis of amikacin's activity against resistant bacterial strains.
• Assessment of its pharmacokinetic profile and therapeutic index.

Main Results:

• Amikacin exhibits high activity against Gram-negative bacteria, including resistant strains.
• It shows synergistic effects when combined with beta-lactam antibiotics and third-generation cephalosporins.
• Amikacin has a favorable therapeutic index with predictable serum concentrations and manageable toxicity.

Conclusions:

• Amikacin is the preferred aminoglycoside due to its activity against resistant organisms, low resistance potential, and favorable pharmacokinetics.
• It is a valuable component of empiric antibiotic regimens for suspected sepsis in immunocompromised hosts.
• Its combination with other antibiotics enhances treatment outcomes in severe infections.